Efficacy, Safety, and Tolerability of Subcutaneous Efgartigimod PH20 in Chinese Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Prespecified Subpopulation Analysis of the Multicentre, Randomised-Withdrawal, Double-Blind, Placebo-Controlled, Phase II ADHERE Trial
皮下注射 Efgartigimod PH20 治疗中国慢性炎症性脱髓鞘性多发性神经病患者的疗效、安全性和耐受性：一项多中心、随机撤药、双盲、安慰剂对照的 II 期 ADHERE 试验的预设亚组分析
期刊:Journal of Clinical Neurology
影响因子:3.1
doi:10.3988/jcn.2025.0247
Lin, Jie; Ding, Man; Wang, Qinzhou; Chang, Ting; Zhao, Yuanqi; Da, Yuwei; Tan, Song; Hong, Daojun; Jiang, Haishan; Zou, Zhangyu; Yang, Huan; Bu, Bitao; Liang, Hui; Wang, Yiqi; Guo, Aihong; He, Dian; Wang, Yuzhong; Ding, Jing; Guo, Junhong; Shi, Jianquan; Zhang, Yali; Liu, Jing; Liu, Jia; Chen, Lijuan; Wu, Junlong; Shao, Jing; Hofman, Erik; Hoorick, Benjamin Van; Mole, Trevor; Li, Wei; Lu, Zuneng
